
A true revolution in blood tests for cancer detection with cutting-edge technology capable of efficiently isolating and analyzing CTCs from blood. Its main advantages are the ability to isolate a single tumor cell from a pool of more than 50 billion cells; the automation of its processes, which avoids human error; the isolated tumor cells are compatible with traditional molecular biology techniques so that subsequent functional analysis can be performed; and that this technology was developed by the Delee team, which dramatically reduces the cost per unit, resulting in competitive prices.
 CEOLiza Velarde CEOLiza Velarde
 CFOJuan Felipe Yee CFOJuan Felipe Yee
 CTOAlejandro Abarca CTOAlejandro Abarca



